“Dimethyl sulfoxide (DMSO) as a potential contrast agent for brain tumors”, by Delgado-Goñi T, Martín-Sitjar J, Simões RV, Acosta M, Lope-Piedrafita S, Arús C.; NMR in Biomedicine. 2012.DOI: 10.1002/nbm.2832.
Identifying the type of brain tumor helps doctors determine the most appropriate course of treatment. Brain tumor diagnosis usually involves a neurological examination, brain scans, and/or an analysis of the brain tissue. Nowadays, the biopsy, although it is a very invasive procedure, is the most accurate method of obtaining a diagnosis. Continue reading DMSO as a magnetic resonance contrast agent for brain tumors
“Efficient γ-amino-proline-derived cell penetrating peptide-superparamagnetic iron oxide nanoparticle conjugates via aniline-catalyzed oxime chemistry as bimodal imaging nanoagents”, by Cavalli S, Carbajo D, Acosta M, Lope-Piedrafita S, Candiota AP, Arús C, Royo M, Albericio F; Chem. Commun 48 (2012) p. 5322. DOI: 10.1039/C2CC17937G
Recent advances in nanotechnology have offered new opportunities for detection, prevention, and treatment of different diseases. In this respect engineered superparamagnetic iron oxide nanoparticles (SPIONs) represent an advanced tool in nanomedicine because they can be loaded in a multiple and orthogonal way with drugs and probes in order to simultaneously act as molecular imaging agents and drug carriers. Continue reading Novel MRI contrast agents: peptide-SPION conjugates